To determine whether cluster analysis of the differentially regulated annexins and S100A genes (Fig 8A) would confer any concessionary changes on patient prognostic outcome, we used an unbiased combinational approach, which assessed treatment outcome based on the overall (combined) annexin and S100A overexpression profile in ER+ breast cancer patients (Fig 8B). This evidence concerns the gene ESR1 and breast carcinoma.